Celanese (CE) to Highlight Innovations in EVA Polymers

A generic image of a stock chart on a display
Credit: Shutterstock photo

Chemical and advanced materials maker - Celanese CorporationCE , announced that it will exhibit, "Driving Ophthalmic Drug Delivery Innovation with EVA" on Sep 20 at the 2016 Targeting Ocular Disorders Conference in Boston, MA.

Celanese is working with its customers to make state-of-the-art drug delivery systems using the pharmaceutical material solutions of its EVA polymers business. The Celanese EVA polymers business' broad medical and pharmaceutical polymer portfolio aids in making comfortable and easy-to-use drug delivery devices and implants. The business has come up with innovations in its EVA polymer portfolio that create broader device and implant design options to cater to the changing drug delivery needs.

At the presentation, Celanese will highlight the product called VitalDose EVA which is a controlled-release excipient ideal for use in pharmaceutical drug delivery implants that require a consistent release of active ingredients. VitalDose EVA polymers may be used standalone or in combination with other excipients and/or additives to achieve desired release-rate profiles. The presentation will feature how VitalDose EVA polymers can cater to the needs of the patient in ophthalmic drug delivery, mainly patient compliance, drug dosing and sustained drug release to various parts of the eye.



Celanese kept its earnings streak alive with a beat in second-quarter 2016. The company reported adjusted earnings of $1.59 per share in the quarter. The figure was a penny higher than the prior-year quarter tally and above the Zacks Consensus Estimate of $1.55.

Celanese reported quarterly sales of $1,351 million, missing the Zacks Consensus Estimate of $1,418 million. The top line declined roughly 8.5% year over year.

The company noted that recent events have added further uncertainties to economic growth expectations. However, it projects a relatively stable economic landscape across the U.S. and Europe for the rest of 2016. The company's Materials Solutions unit provides the best package of global presence, product portfolio and applications expertise in the industry, along with a rigorous pipeline process. This enables it to provide value to its customers and in turn, boost earnings at business.

Celanese, however, is exposed to pricing pressure and is still witnessing soft acetyl demand in China given the sluggish economic conditions. Acetyl intermediates margins are anticipated to remain strained in the near term.

Celanese currently carries a Zacks Rank #4 (Sell).

Better-ranked companies in the chemical space include Innophos Holdings Inc IPHS , Innospec Inc. IOSP and Stepan Company SCL , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CELANESE CP-A (CE): Free Stock Analysis Report

INNOPHOS HLDGS (IPHS): Free Stock Analysis Report

INNOSPEC INC (IOSP): Free Stock Analysis Report

STEPAN CO (SCL): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More